CaPtivate
Pharmaceuticals
 

 

 

Management

Tulin-Web Profile v:shapes=Tülin U. Morçöl, PhD
President and Chief Scientific Officer

Prior to founding CaPtivate Pharmaceuticals in 2011, Dr. Morçöl worked for BioSante Pharmaceuticals, Inc. for 13 years; first as Associate Director of Research and Development and then Director of Preclinical Development. During her tenure at BioSante, she focused on developing formulation strategies for therapeutic drugs and vaccines using company's CaP nanoparticle (CaP) technology for non-invasive administration, and developing large scale manufacturing processes for CaP. She is inventor /co-inventor in several US Patents related to CaP technology. At BioSante, she expanded the applications of CaP-based technologies in protein purification, nutritional supplement, and developing formulations for esthetic medicine. In 2006, she led the formation of BioSante Pennsylvania Research Laboratory which is currently occupied by CaPtivate Pharmaceuticals. Before joining BioSante, she worked at the Morehouse School of Medicine (MSM), Department of Neurosciences, Atlanta, GA, for four years. Her research at MSM involved circadian rhythm and neurodegenerative diseases of the brain, such as Parkinson's Disease. Before moving to USA, Dr. Morçöl worked as a scientist for the Turkish Atomic Energy Agency for 5 years. She received her BS and MS degrees in Chemical Engineering in Turkey. She earned her PhD in Biochemical Engineering from Virginia Polytechnic Institute and State University. At Virginia Tech, she studied under the mentorship of Dr. William H. Velander and as a member of his Transgenic Animal Research Team. Her PhD research involved development of large-scale processes for the purification of recombinant blood clotting factors (e.g. Protein C) from the milk of transgenic bio-reactors.